Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis

Immunotherapy has evolved as a powerful tool for the treatment of B-cell malignancies, and patient outcomes have improved by combining therapeutic antibodies with conventional chemotherapy. Overexpression of antiapoptotic B-cell lymphoma 2 (Bcl-2) is associated with a poor prognosis, and increased l...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogiatzi, Fotini, Heymann, Julia, Müller, Kristina, Winterberg, Dorothee, Drakul, Aneta, Rösner, Thies, Lenk, Lennart, Heib, Michelle, Gehlert, Carina Lynn, Cario, Gunnar, Schrappe, Martin, Claviez, Alexander, Bornhauser, Beat, Bourquin, Jean-Pierre, Bomken, Simon, Adam, Dieter, Frielitz, Fabian-Simon, Maecker-Kolhoff, Britta, Stanulla, Martin, Valerius, Thomas, Peipp, Matthias, Kellner, Christian, Schewe, Denis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631674/
https://www.ncbi.nlm.nih.gov/pubmed/35820018
http://dx.doi.org/10.1182/bloodadvances.2022007364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631674/
https://www.ncbi.nlm.nih.gov/pubmed/35820018
http://dx.doi.org/10.1182/bloodadvances.2022007364

Ejemplares similares